Lilly’s Abemaciclib Efficacy Data At ASCO Could Hold Up To Accelerated Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Data presented by Eli Lilly at ASCO could support accelerated approval of abemaciclib but a tolerability issue could impact its competitive position in the commercial market versus Pfizer’s Ibrance.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.